Nephrol Dial Transplant (2001) 16: 1968-1971
© 2001 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
Endothelial dysfunction and inflammation—is there a link?
Department of Internal Medicine, Division of Nephrology, University of California Davis, Davis, CA, USA
Introduction
The endothelium is a functional barrier between vessel wall and blood stream that for a long time has been regarded as a relatively inert container for blood. However, the last 20 years, researchers have found an extraordinary variety of important endothelial functions, including control of coagulation, fibrinolysis, vascular tone, growth, and immune response. The endothelium modulates vascular tone by releasing a number of vasoactive substances including nitric oxide (NO). It is now clear that dysfunction of the endothelium disturbs the physiological protective regulatory balance, which is a critical factor in the atherosclerotic disease progression. Thus, endothelial dysfunction occurs in many diseases/disorders associated with an increased cardiovascular risk, such as essential hypertension [1], dyslipidaemia [2], smoking [3] and mental stress [4].
The significant burden of atherosclerotic cardiovascular disease (CVD) in end-stage renal disease (ESRD) has been recognized since more than 25 years [
Endothelial dysfunction is a prominent feature of ESRD
Strong relation between inflammation and endothelial dysfunction in non-renal patient groups
Various infections cause endothelial dysfunction
Is tumour necrosis factor-
(TNF-) the key mediator of endothelial dysfunction?
Anti-inflammatory treatment strategies improve endothelial function
Conclusion
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Xu and M.-H. Zou Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction Circulation, September 29, 2009; 120(13): 1266 - 1286. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle? Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kato, B. Lindholm, J. Axelsson, R. A. Qureshi, P. Barany, O. Heimburger, J.-A. Gustafsson, P. Stenvinkel, and L. Nordfors Association between oestrogen receptor {alpha} gene polymorphism and mortality in female end-stage renal disease patients Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2571 - 2577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gong, A. Rifai, and L. D. Dworkin Anti-Inflammatory Effect of Hepatocyte Growth Factor in Chronic Kidney Disease: Targeting the Inflamed Vascular Endothelium J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2464 - 2473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jacobi, S. Sela, H. I. Cohen, J. Chezar, and B. Kristal Priming of polymorphonuclear leukocytes: a culprit in the initiation of endothelial cell injury Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2051 - H2058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. C. Grooteman and M. J. Nube Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: does it really matter? Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2965 - 2970. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Naumnik, J. Borawski, K. Pawlak, and M. Mysliwiec Effect of Hemodialysis on Plasma Levels of Vascular Endothelial Markers Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 245 - 250. [Abstract] [PDF]
|
|